NDA for Inveltys to treat postoperative inflammation, pain accepted

The FDA has accepted a new drug application for Inveltys, a product candidate for the treatment of inflammation and pain in ocular surgery patients, according to a press release from Kala Pharmaceuticals.

If approved, Inveltys (KPI-121 1%) would be the first twice-daily ocular corticosteroid indicated for the treatment of postoperative ocular inflammation and pain, as all other drugs currently on the market are indicated for four times a day, the release said.

It uses Kala’s mucus-penetrating particle technology to enhance drug penetration and distribution in ocular tissues.

In two phase 3 clinical trials, Inveltys showed statistical significance for its primary efficacy endpoints of complete resolution of inflammation and pain at day 8 through day 15 compared with placebo, according to the release.

Inveltys has a Prescription Drug User Fee Act date of Aug. 24.

The FDA has accepted a new drug application for Inveltys, a product candidate for the treatment of inflammation and pain in ocular surgery patients, according to a press release from Kala Pharmaceuticals.

If approved, Inveltys (KPI-121 1%) would be the first twice-daily ocular corticosteroid indicated for the treatment of postoperative ocular inflammation and pain, as all other drugs currently on the market are indicated for four times a day, the release said.

It uses Kala’s mucus-penetrating particle technology to enhance drug penetration and distribution in ocular tissues.

In two phase 3 clinical trials, Inveltys showed statistical significance for its primary efficacy endpoints of complete resolution of inflammation and pain at day 8 through day 15 compared with placebo, according to the release.

Inveltys has a Prescription Drug User Fee Act date of Aug. 24.